Navigating the 2021 update to the IDSA/SHEA <i>Clostridioides difficile</i> guidelines: An ethical approach to equitable patient care

Shoff, Christopher; Spires, S Shaefer; Yen, Christina; Advani, Sonali D

doi:10.1017/ash.2022.49

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clostridioides difficile infection (CDI) is the most common cause of post-antibiotic diarrhea worldwide [ 1 ]. The condition of Clostridioides difficile infection (CDI) is characterized by diarrhea, and diagnosis typically requires the presence of diarrhea in conjunction with at least one of the following criteria, as outlined by IDSA/SHEA [ 2 ] or ESCMID [ 3 ] guidelines: (1) detection of toxin A and/or B in the stool or detection of the bacterial strain by another method, (2) identification of pseudomembranous enteritis during endoscopy or surgery, or (3) confirmation of pseudomembranous enteritis on histopathology [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Mortality in clostridioides difficile infection among patients hospitalized at the university clinical hospital in Wroclaw, Poland – a 3-year observational study

Drobnik,

Pobrotyn,

Belovičová

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

Background In the last two decades, a significant increase in the number of Clostridioides difficile infection (CDI) cases has been observed. It is understandable to attempt to determine the factors that can predict the severity of the course of the infection and identify patients at risk of death. This study aimed to analyze the factors affecting the incidence and mortality of CDI in inpatient treatment at the University Clinical Hospital in Wrocław in 2016–2018. Methods Statistical analysis of data obtained from patients’ medical records was performed. Only patients with symptoms of infection and infection confirmed by laboratory tests were enrolled in the study. When analyzing the number of deaths, only adult patients who died in hospital wards were included. The quantitative data including laboratory tests, used antibiotics and Nutritional Risk Screening (NRS) were assessed. Also, the qualitative data such as sex, year of hospitalization, occurrence of diarrhoea on admission to the hospital, presence of additional diseases, as wee ad the use of antibacterial drugs or proton pump blockers and ranitidine during hospitalization were analyzed. Results A total of 319 adult CDI patients (178 women and 141 men) were enrolled of which 80 people died (50 women and 30 men). The mean age of the patients was 72.08 ± 16.74 years. Over the entire period studied, the morbidity was 174 cases per 100,000 hospitalizations while mortality was 25.08%. The group of deceased patients was characterized by: older age (by 9.24 years), longer duration of hospitalization (by 10 days), reduced albumin levels (Rho = -0.235, p < 0.001), higher urea levels, use of more antibiotics, higher risk of malnutrition in NRS (Rho = 0.219, p < 0.001), higher incidence of sepsis, heart failure, stroke, hypothyroidism. Pneumonia was diagnosed twice as often. It was also shown that deceased patients were significantly more likely to take penicillin and fluoroquinolones. Conclusions In this study, the morbidity was lower, but mortality was higher compared to similar hospitals in Poland. CDI patients were characterized by older age, multimorbidity, extended hospitalization, and the use of broad-spectrum antibiotics. Risk factors for death included advanced age, prolonged hospital stays, lower albumin, higher urea, malnutrition, and comorbidities like heart failure, stroke, pneumonia, sepsis, and hypothyroidism. Increased antibiotic use, particularly penicillin and fluoroquinolones, was associated with a higher mortality risk.

show abstract

Section: Introductionmentioning

confidence: 99%

Mortality in clostridioides difficile infection among patients hospitalized at the university clinical hospital in Wroclaw, Poland – a 3-year observational study

Drobnik,

Pobrotyn,

Belovičová

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

“…Unfortunately, the higher cost of fidaxomicin is limiting its use, and the continued alteration to the colonic microbiota by these antibiotics, lead to patients experiencing recurring disease due to the presence of C. difficile spores within the gastrointestinal tract or in the surrounding environment. 21 , 22 …”

Section: Introductionmentioning

confidence: 99%

Gut associated metabolites and their roles in Clostridioides difficile pathogenesis

Aguirre

Sorg

2022

Gut Microbes

View full text Add to dashboard Cite

The nosocomial pathogen Clostridioides difficile is a burden to the healthcare system. Gut microbiome disruption, most commonly by broad-spectrum antibiotic treatment, is well established to generate a state that is susceptible to CDI. A variety of metabolites produced by the host and/or gut microbiota have been shown to interact with C. difficile . Certain bile acids promote/inhibit germination while other cholesterol-derived compounds and amino acids used in the Stickland metabolic pathway affect growth and CDI colonization. Short chain fatty acids maintain intestinal barrier integrity and a myriad of other metabolic compounds are used as nutritional sources or used by C. difficile to inhibit or outcompete other bacteria in the gut. As the move toward non-antibiotic CDI treatment takes place, a deeper understanding of interactions between C. difficile and the host’s gut microbiome and metabolites becomes more relevant.

show abstract

Navigating the 2021 update to the IDSA/SHEA Clostridioides difficile guidelines: An ethical approach to equitable patient care

Cited by 2 publications

References 18 publications

Mortality in clostridioides difficile infection among patients hospitalized at the university clinical hospital in Wroclaw, Poland – a 3-year observational study

Mortality in clostridioides difficile infection among patients hospitalized at the university clinical hospital in Wroclaw, Poland – a 3-year observational study

Gut associated metabolites and their roles in Clostridioides difficile pathogenesis

Contact Info

Product

Resources

About